Inflammatory Bowel Disease
Found 78 articles
Polpharma Biologics' investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®
Polpharma Biologics announced topline results demonstrating the pharmacokinetic and pharmacodynamics comparability of its biosimilar candidate PB016 to its reference drug, Entyvio®*.
The European Commission granted marketing authorization in the EU to treat patients 16 years of age and older with moderately to severely active ulcerative colitis.
Devonian Bolsters Intellectual Property With Issuance of U.S. Patent Covering a Method of Treatment of Inflammatory Bowel Disease
Devonian Health Group Inc. today announced that the United States Patent and Trademark Office (“ USPTO ”) has issued patent no. 11,723,938 B2 entitled, “ Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease. ”
EnLiSense CCM Advances Validation of Real-Time IBD Inflammatory Biomarker Monitoring with Two Recent Peer-Reviewed Longitudinal Studies
EnLiSense CCM, a pioneer in non-invasive sweat-sensor technology for real-time health monitoring, is thrilled to announce a groundbreaking advancement in the world of Inflammatory Bowel Disease management.
Spyre Therapeutics, Inc. announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 125,000 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended.
Imagine a day when people can enjoy snacking on foods designed to "re-calibrate" their microbiomes—that vast population of friendly bacteria living in our intestines—in order to promote a healthy immune system and decrease infections or chronic inflammation.
Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD)
Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD).
The private placement from existing and new investors extends the company’s cash runway into the second half of 2026 and will help take two candidates for inflammatory bowel disease into the clinic in 2024.
Geneoscopy and Adiso Therapeutics Announce Strategic Collaboration to Investigate New Therapeutic Options for Patients with Inflammatory Bowel Disease
Geneoscopy, Inc. and Adiso Therapeutics, Inc. today announced a strategic collaboration to further treatment options available for patients with inflammatory bowel disease (IBD).
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
Sosei Group Corporation announces it has initiated discussions with GSK to regain full ownership of GSK4381406, a highly selective first-in-class, oral GPR35 agonist in development under a Global Collaboration and License Agreement with GSK as a potential new treatment for Inflammatory Bowel Diseases.
After a negative review by an Independent Data Monitoring Committee, InDex Pharmaceuticals has decided to discontinue the late-stage CONCLUDE program evaluating its cobitolimod in ulcerative colitis.
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
ZyVersa Therapeutics, Inc. announces publication of an article in the peer-reviewed Biomedical Journal demonstrating that inhibiting NLRP3 inflammasomes in an IBD animal model attenuates intestinal inflammation and tissue damage, leading to significant improvements in IBD symptoms, and restoration of normal intestinal microbial flora.
Novel Immune Modulator Has Potential to Change Treatment Approach in Rheumatoid Arthritis and Ulc...
11/3/2023A first-in-class clinical trial will initiate this quarter to determine if a checkpoint agonist can down-regulate activated T cells to help reduce inflammation and tissue damage in patients with moderate-to-severe ulcerative colitis (UC).
The regulator has approved the first-ever subcutaneous version of infliximab, an IgG1 monoclonal antibody, commonly sold by Johnson & Johnson under the brand name Remicade.
Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease
Celltrion USA announced that the U.S. Food and Drug Administration has approved ZYMFENTRA® for maintenance therapy in adults with moderately to severely active ulcerative colitis and Crohn’s disease following treatment with an infliximab product administered intravenously.
In a follow-up readout, data from the head-to-head SEQUENCE study showed that AbbVie’s Skyrizi induced better rates of steroid-free remission in Crohn’s disease than Johnson & Johnson’s Stelara.
The regulator's approval of oral, once-daily etrasimod, to be marketed as Velsipity, was based on favorable Phase III safety and efficacy data showing significant clinical remission of ulcerative colitis.
Geneoscopy Inc. will present at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting in Vancouver, Canada, Oct. 20-25, highlighting how its novel platform technology is being used to develop noninvasive diagnostic and precision medicine tools for gastrointestinal (GI) diseases, such as colorectal cancer (CRC) and inflammatory bowel disease (IBD).
The French pharma paid $500 million upfront, with up to $1 billion in future milestone payments, to co-develop and co-commercialize Teva’s Phase II anti-TL1A antibody for inflammatory bowel disease.
Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announce a collaboration to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.